![Claude Wischik](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Claude Wischik
Chief Executive Officer at TauRx Pharmaceuticals Ltd.
Claude Wischik active positions
Companies | Position | Start | End |
---|---|---|---|
TauRx Pharmaceuticals Ltd.
![]() TauRx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology TauRx Pharmaceuticals Ltd. developes drugs and diagnostics for neurodegenerative diseases. its pipeline includes LMTX, a tau aggregation inhibitor (TAI) for Alzheimer?s and Behavioural variant frontotemporal dementia diseases; anti-synuclein, a synuclein protein; early-stage compounds for use in therapies for neurodegenerative diseases; and diagnostic tests that assist clinicians in detecting and confirming the nature of a disease and monitoring the effects of therapy. The company was founded by Claude Wischik in 2002 and is headquartered in Singapore. | Chief Executive Officer | 31/12/2001 | - |
Chairman | 31/12/2001 | - | |
Founder | 31/12/2001 | - | |
TauRx Therapeutics Ltd.
![]() TauRx Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology TauRx Therapeutics Ltd. develops treatments and diagnostics for a range of neurodegenerative diseases. It offers tau aggregation inhibitor, LMTX, a global Phase 3 clinical trials for Alzheimer’s and behavioural-variant Frontotemporal Dementia (bvFTD). LMTXT. The company was founded by Claude Wischik and K M Seng in 2002 and is headquartered in Singapore. | Chairman | 31/12/2001 | - |
Founder | 31/12/2001 | - |
Career history of Claude Wischik
Statistics
International
Singapore | 3 |
Operational
Founder | 2 |
Chairman | 2 |
Chief Executive Officer | 1 |
Sectoral
Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 2 |
---|---|
TauRx Pharmaceuticals Ltd.
![]() TauRx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology TauRx Pharmaceuticals Ltd. developes drugs and diagnostics for neurodegenerative diseases. its pipeline includes LMTX, a tau aggregation inhibitor (TAI) for Alzheimer?s and Behavioural variant frontotemporal dementia diseases; anti-synuclein, a synuclein protein; early-stage compounds for use in therapies for neurodegenerative diseases; and diagnostic tests that assist clinicians in detecting and confirming the nature of a disease and monitoring the effects of therapy. The company was founded by Claude Wischik in 2002 and is headquartered in Singapore. | Health Technology |
TauRx Therapeutics Ltd.
![]() TauRx Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology TauRx Therapeutics Ltd. develops treatments and diagnostics for a range of neurodegenerative diseases. It offers tau aggregation inhibitor, LMTX, a global Phase 3 clinical trials for Alzheimer’s and behavioural-variant Frontotemporal Dementia (bvFTD). LMTXT. The company was founded by Claude Wischik and K M Seng in 2002 and is headquartered in Singapore. | Health Technology |
- Stock Market
- Insiders
- Claude Wischik
- Experience